SNN Overview

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

Wall Street analysts forecast SNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNN is35.75 USD with a low forecast of 34.00 USD and a high forecast of 37.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Smith & Nephew PLC revenue for the last quarter amounts to NaN USD, decreased

Smith & Nephew PLC. EPS for the last quarter amounts to USD, decreased

Smith & Nephew PLC (SNN) has 17349 emplpoyees as of March 02 2026.

Today SNN has the market capitalization of 15.66B USD.